Alnylam Pharmaceuticals (ALNY) AI Analysis

AI Score 85. Alnylam Pharmaceuticals has a strong market capitalization of approximately $21.57 billion and impressive profitability metrics, including a net profit margin of 54.3%. The company also shows robust growth potential with a price-to-earnings ratio of about 7.9 and a solid pipeline of RNAi-based therapies, indicating strong future revenue prospects

Summary

Alnylam Pharmaceuticals, Inc. operates in the Healthcare sector and Biotechnology industry. The company reports a P/E ratio of 8.1 and a net margin of 54.3%.

Valuation

The P/E ratio of 8.1 is low relative to the company’s reported profitability, while price-to-book is 6.1. The available facts do not provide revenue, earnings estimates, or price-trend data for a fuller valuation assessment.

Quality

A net margin of 54.3% indicates strong reported profitability. However, the provided facts do not include balance-sheet, cash-flow, or return-on-capital measures.

Growth

No revenue, earnings-growth, guidance, or analyst-estimate information is provided. Growth cannot be assessed from the available facts.

Risks

The shares trade at 6.1 times book value, which may leave valuation sensitive to changes in expectations. There is no dividend yield, and the available facts provide limited visibility into growth and financial durability.